%PDF-1.4
%
73 0 obj
<>
endobj
70 0 obj
<>
endobj
125 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-06-03T12:23:07Z
2024-03-29T01:11:10-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T01:11:10-07:00
application/pdf
Heather
2004-452.july
uuid:b1c77775-1dd1-11b2-0a00-5c0827bd7200
uuid:b1c77778-1dd1-11b2-0a00-880000000000
endstream
endobj
59 0 obj
<>
endobj
60 0 obj
<>
endobj
74 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
26 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 53 0 R/Type/Page>>
endobj
147 0 obj
[151 0 R]
endobj
148 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 736.1941 Tm
[(of hospital-diagnosed cases, 1963-1982. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1997;40:441-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Silman )54.8 (A, Jannini S, Symmons D, Bacon P)110.7 (.)-0.1 ( )54.8 (An epidemiological)]TJ
1.675 -1.25 Td
[(study of scleroderma in the )17.7 (W)79.9 (est Midlands. Br J Rheumatol)]TJ
0 Tc 0 Tw T*
(1988;27:286-90.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Silman )54.8 (AJ, Howard )36.8 (Y)128.9 (, Hicklin )54.8 (AJ, Black C. Geographical)]TJ
1.675 -1.25 Td
(clustering of scleroderma in south and west London. Br J)Tj
T*
(Rheumatol 1990;29:93-6.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Roberts-Thomson PJ, Jones M, Hakendorf P)110.7 (, et al. Scleroderma in)]TJ
2.175 -1.25 Td
[(South )54.8 (Australia: epidemiological observations of possible)]TJ
T*
(pathogenic significance. Int Med J 2001;31:220-9.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Thompson )54.8 (AE, Pope JE. Increased prevalence of scleroderma in)]TJ
2.1381 -1.25 Td
[(Southwestern Ontario: )54.8 (A)-220.1 (cluster analysis. J Rheumatol)]TJ
0 Tc 0 Tw T*
(2002;29:1867-73.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Bryan C, Howard )36.8 (Y)128.9 (, Brennan P)110.7 (, et al. Survival following the onset)]TJ
2.175 -1.25 Td
(of scleroderma: results from a retrospective inception cohort study)Tj
T*
[(of the UK patient population. Br J Rheumatol 1996;35:1)36.8 (122-6.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Bryan C, Knight C, Black CM, Silman )54.8 (AJ. Prediction of five-year)]TJ
2.175 -1.25 Td
(survival following presentation with scleroderma; development of a)Tj
T*
[(simple model using three disease factors at first visit. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:2660-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Lee P)110.7 (, Langevitz P)110.7 (,)-0.1 ( )54.8 (Alderdice CA, et al. Mortality in systemic)]TJ
2.175 -1.25 Td
(sclerosis \(scleroderma\). Q J Med 1992;82:139-48.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Abu-Shakra M, Lee P)110.7 (. Mortality in systemic sclerosis: a)]TJ
2.175 -1.25 Td
(comparison with the general population. J Rheumatol)Tj
0 Tc 0 Tw T*
(1995;22:2100-2.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Silman )54.8 (AJ. Scleroderma and survival. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1991;50:267-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (MacGregor )54.8 (AJ, Canavan R, Knight C, et al. Pulmonary)]TJ
2.175 -1.25 Td
(hypertension in systemic sclerosis: risk factors for progression and)Tj
T*
(consequences for survival. Rheumatology Oxford 2001;40:453-9.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Denton CP)110.7 (, Cailes JB, Phillips GD, et al. Comparison of Doppler)]TJ
2.175 -1.25 Td
(echocardiography and right heart catheterization to assess)Tj
T*
(pulmonary hypertension in systemic sclerosis. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:239-43.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Nauser )17.7 (TD, Stites SW)91.7 (. Diagnosis and treatment of pulmonary)]TJ
2.175 -1.25 Td
[(hypertension. )54.8 (Am Fam Physician 2001;63:1789-98.)]TJ
30.825 45 Td
[(20.)-875.1 (Battle R)54.8 (W)91.9 (, Davitt MA, Cooper SM, et al. Prevalence of pulmonary)]TJ
2.175 -1.25 Td
[(hypertension in limited and dif)17.7 (fuse scleroderma. Chest)]TJ
0 Tc 0 Tw T*
[(1996;1)36.9 (10:1515-9.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Koh ET)73.9 (, Lee P)110.7 (, Gladman DD, )54.8 (Abu-Shakra M. Pulmonary)]TJ
2.175 -1.25 Td
[(hypertension in systemic sclerosis: )54.8 (An analysis of 17 patients. Br J)]TJ
T*
(Rheumatol 1996;35:989-93.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Steen )17.7 (V)128.9 (, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)54.8 (. Predictors of isolated pulmonary)]TJ
2.175 -1.25 Td
(hypertension in patients with systemic sclerosis and limited)Tj
T*
[(cutaneous involvement. )54.8 (Arthritis Rheum 2003;48:516-22.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Rich S, editor)54.8 (. Executive summary from the )17.7 (W)79.9 (orld Symposium on)]TJ
2.175 -1.25 Td
[(Primary Pulmonary Hypertension 1998. Geneva: )17.7 (W)79.9 (orld Health)]TJ
0 Tw T*
[(Or)17.7 (ganization.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Badesch DB, )17.7 (T)69.9 (apson )17.7 (VF)79.7 (, McGoon MD, et al. Continuous)]TJ
2.175 -1.25 Td
(intravenous epoprostenol for pulmonary hypertension due to the)Tj
T*
[(scleroderma spectrum of disease: )54.8 (A)-220.1 (randomized controlled trial.)]TJ
T*
(Ann Intern Med 2000;132:425-34.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy in patients)]TJ
2.175 -1.25 Td
(with pulmonary arterial hypertension. N Engl J Med 2002;)Tj
0 Tc 0 Tw T*
(346:896-903.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Arcasoy S, Christie J, Ferrari )17.7 (V)128.9 (, et al. Echocardiographic)]TJ
2.175 -1.25 Td
(assessment of pulmonary hypertension in patients with advanced)Tj
T*
[(lung disease. )54.8 (Am J Respir Crit Care Med 2003;167:735-40.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Chang B, )17.7 (W)39.8 (igley FM, )17.7 (White B, et al. Scleroderma patients with)]TJ
2.175 -1.25 Td
(combined pulmonary hypertension and interstitial lung disease. )Tj
T*
(J Rheumatol 2003;30:2398-405.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Schachna L, )17.7 (W)39.9 (igley FM, Chang B, et al. )54.8 (Age and risk of)]TJ
2.175 -1.25 Td
(pulmonary arterial hypertension in scleroderma. Chest)Tj
0 Tc 0 Tw T*
(2003;124:2098-104.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Simonneau G, Barst R, Galie N, et al. Continuous subcutaneous)]TJ
2.175 -1.25 Td
(infusion of treprostinil, a prostacyclin analogue, in patients with)Tj
T*
(pulmonary arterial hypertension: a double-blind, randomized,)Tj
T*
[(placebo-controlled trial. )54.8 (Am J Respir Crit Care Med 2002;)]TJ
0 Tc 0 Tw T*
(165:800-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (Mukerjee D, St-Geor)17.7 (ge D, Coleiro B, et al. Prevalence and outcome)]TJ
2.175 -1.25 Td
(in systemic sclerosis associated pulmonary arterial hypertension:)Tj
T*
[(application of a registry approach. )54.8 (Ann Rheum Dis 2003;)]TJ
0 Tc 0 Tw T*
(62:1088-93.)Tj
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 53.8216 56.7343 Tm
(1278)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:7)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
53 0 obj
<>stream
8;Z\7$#[X7%+G5@W:-gd9p%W'(=!*minC5"'T&[s-glik"ab[aIrq/QV*0oa9NT+;.IT7Eim\
_M,sWc)TV)cWi;?43F8LfsDeq6^Fr1J6jWa[6=!"1C.:"eH?j$+
p(L>/UeA?aArn@Mk7`Ad@dTp)>@'8%Kqi%ZH?A`_/Mq[#?..q1d'YJhilQOF13nJ^
N(hke4b_OH;Us(&de&l2U@]`:]M/Nirto.7BB[7C0^ihf?gJX7LU\L,NdL51FpqR?
-q,V(>Sjl&741p5D7F7:QR)6q,^2<>[3*X<8WoqG!5fYGRC+bOn=(SE!\>iNXJ'@'
$f.5BS^1E?[2"*=d_K[C3Hg(!7^#K?<4R)7'#>%cp+(_"E2g`$
',,9q,`^YmC!f[h3+)1HJR%LRg@IVn;>%%+Jomfm3O_0:Clo&g$AimEmWLJ0@++3K
mN'Qlc=U<\rah_42_3e[p'G,3=qbpQN4UbXh:-2Kq/tZqA4oQ@&rB"#O[pbC_nNq7
bLb^Fiq;9"#i7,tMc`19-W^![!6deW#6~>
endstream
endobj
57 0 obj
[/Indexed/DeviceRGB 255 56 0 R]
endobj
56 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
88 0 obj
<>
endobj
76 0 obj
<>
endobj
112 0 obj
<>
endobj
130 0 obj
<>
endobj
77 0 obj
<>
endobj
103 0 obj
<>stream
H|UkPWfqiGvBTVQX"n@^( dAGf%YF
B,|l("`d+ir6dVnݪSn:߹8fm8na&EmXJ$LV"8ZclB)"%FWh+n;ueZFฬbOw,ft~A;{d|w*LFO/Q7e)~mjVU<GLf0jZ!NUkO)*n^įפjӳtj/W&.y37h5*Fm7SdV[LcsNX(&zO87_ZVV_IhI{օD1,"JòpY
Mf͵a{mg8Ψ
;vN\2yYYcXʞj's;`}af;;y0Wy9/7k ۜ6RLXCb}G"U;_a"2Xa|nfggz":Ozp9,x \>~^-BВU0h+|2W&a 0a3{-%Z#R#Gr69myDC6~s@Rheȕ@'|H#- )@D@$Yu25%E߭06r2}3!J7# %ǥ{p$I%p>f~'{l +8@R3
\~kk3a w8tUeU#ꪪ)RQor}ġEey %rmy$plnET ̄-M#2乙m,&Zt?W!tWY8;P:
N"nuzA M
دlX0 ɋO Fnum2i_VFloUJYYҪRj'W:o3{"|6E)d}/)XF;+I胛D%yҋH!jIk
"Iyqw%P(|+t@HWJHAa`Fwv7V7#?Ukނa1u9rV>ےru
mhxFu
i^*Q<